This inventor holds 4 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents. Top assignees: National Institute of Health and Medical Research, Universitè De Montpellier, Yeda Research and Develpment & Co. Ltd. Active years: 2015-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 1,853 
2 out of 298 
2 out of 1,168 Years Active: 2015-2020
Title: Nadege Gaborit - Innovator in Antibody Research
Introduction
Nadege Gaborit is a notable inventor residing in Rehovot, Israel, recognized for her contributions to the field of biotechnology. With a focus on developing innovative therapeutic antibodies, she has significantly impacted cancer treatment through her research and patented inventions.
Latest Patents
Nadege Gaborit is credited with two patents. Her latest inventions include the "Neuregulin Allosteric Anti-HER3 Antibody," which relates to a class of antibodies that target the human HER3 protein. This disclosure details the non-competitive allosteric anti-human-HER3 antibodies and their applications in both diagnostic and therapeutic methodologies. The second patent, concerning "Anti-Human HER3 Antibodies and Uses Thereof," provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3. This invention holds particular promise for competing with existing antibodies that target the same domain, thereby enhancing cancer treatment options.
Career Highlights
Over the course of her career, Nadege has worked with esteemed institutions including Université de Montpellier and the Institut National de la Santé et de la Recherche Médicale (Inserm). Her academic and professional experiences have contributed to her innovative approaches in antibody research and development.
Collaborations
Throughout her career, Nadege has collaborated with notable colleagues such as Thierry Chardes and André Pelegrin, further enhancing her research and the development of her patents. These partnerships have enabled her to foster innovative breakthroughs in the medical and therapeutic fields.
Conclusion
Nadege Gaborit exemplifies the spirit of innovation and discovery in biotechnology, particularly in her pioneering work with anti-HER3 antibodies. Her patents not only contribute to advancing cancer treatment but also reflect her commitment to scientific excellence and collaboration. As her research continues to evolve, it holds the potential to significantly impact therapeutic strategies in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile